Daniela Salvemini, Ph.D.
In a recent paper published in the journal Pain, Saint Louis University researchers describe their success in an animal model in turning off the excruciating pain that often accompanies a colorectal cancer drug.
Daniela Salvemini, Ph.D., professor of pharmacology and physiology at SLU, studies pain pathways, the series of interactions between molecular-level components that lead to pain in the body.
One type of pain she examines is chemotherapy induced neuropathic pain (CINP), a debilitating side effect of chemotherapy that can appear as tingling or numbness in the hands and feet, shooting or burning pain in the limbs, or can feel like hot or cold temperature extremes. In addition to causing patients suffering, CINP is often a limiting factor when it comes to treatment.
“Thanks to the increased efficacy of cancer treatment, there are nearly 14 million cancer survivors in the United States,” Salvemini said. “Many of these survivors suffer from long-term side effects of CINP, for which there are no proven strategies for prevention or treatment.
“This is a huge unmet medical need.”
In her current paper, Salvemini studied the platinum-based chemotherapy drug oxaliplatin which is widely used to treat colorectal cancer. Over 60 percent of patients who received oxaliplatin develop CINP, and it can last for years after treatment.
The research team found that the pain pathway associated with this drug was driven by increased expression of an enzyme, adenosine kinase, in astrocytes (a type of central nervous system cell) and decreased adenosine signaling at a key receptor, A3AR. By supplementing this signaling with A3AR agonists, the researchers were able to block the development of CINP without interfering with the anticancer properties of platinum based drugs.
These findings advance researchers’ understanding of pain pathways and provide new information about how drugs may be able to treat chemotherapy pain. Perhaps most encouraging, existing A3AR agonists currently are being studied in advanced clinical trials as novel anticancer agents. This paper makes a strong case for evaluating those drugs for use together with oxaliplatin to limit CINP while treating cancer.
Learn more: In Laboratory, SLU Scientist Turns Off Chemo Pain
The Latest on: Neuropathic pain
[google_news title=”” keyword=”neuropathic pain” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Neuropathic pain
- Prevalence and interference of neuropathic pain in the quality of life in patients with knee osteoarthritison November 27, 2023 at 4:32 pm
With the aging of the population, more patients have complained of pain due to knee Osteoarthritis (OA), and the number of arthroplasties has also increased. The objective of this study is to evaluate ...
- BAY-3178275 by Bayer for Diabetic Neuropathic Pain: Likelihood of Approvalon November 26, 2023 at 4:01 pm
BAY-3178275 is under clinical development by Bayer and currently in Phase I for Diabetic Neuropathic Pain. According to GlobalData, Phase I drugs for Diabetic Neuropathic Pain have a 94% phase ...
- Towards a Definition of Refractory Neuropathic Pain for Epidemiological Researchon November 24, 2023 at 4:00 pm
Background Best current estimates of neuropathic pain (NeuP) prevalence come from studies using various screening detecting pain with probable neuropathic features; the proportion experiencing ...
- Neuropathic Pain: Treatment, Procedure, Cost and Side Effectson November 24, 2023 at 4:00 pm
The greatest challenge that the doctors go through in treating neuropathic pain is to diagnose and detect the underlying cause. The treatment of neuropathic pain is done mostly by pharmaceutical drugs ...
- Pathophysiological Mechanisms of Neuropathic Painon November 22, 2023 at 4:00 pm
At the bedside examination, neuropathic pain can been distinguished from spontaneous pain, (i.e., stimulus independent) and provoked pain. [70] Spontaneous pain can have several different qualities.
- Pain caused by diabetic neuropathy is underestimatedon November 15, 2023 at 1:00 am
One form of this condition is neuropathic pain, which is caused by a lesion or disease of the somatosensory nervous system. While neuropathic pain accounts for 20-25% of chronic pain, it is still ...
- Study ties central neuropathic pain to more severe emotional burdenon November 13, 2023 at 9:00 pm
Central neuropathic pain in MS patients appears to be more severe and widespread than pain in muscles and joints.
- Neuropathic Back-Related Leg Pain is Not Always Persistenton November 6, 2023 at 4:01 pm
At 4 months, 44% of patients with NP at baseline had persistent-NP, and 40% of patients with a clinical diagnosis of sciatica had persistent-NP. Neuropathic back-related leg pain is not always ...
- Best exercises for sciaticaon October 31, 2023 at 5:00 pm
Examples include knee-to-chest stretching exercises and the child’s pose. Sciatica is a type of nerve pain along the sciatic nerve, which runs from the lower back through the hips before ...
via Bing News
